country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-164485

Copy Link Print Information

INI-4001

INI-4001 is a TLR7/8 agonist and vaccine adjuvant. INI-4001 regulates innate and adaptive immune responses by activating murine TLR7 and human TLR7/TLR8. INI-4001 enhances IgG and neutralizing antibody responses against Powassan virus (POWV), reduces viral loads in the brain, liver and spleen, provides complete protection against lethal POWV challenge, and skews immune responses toward a Th1 phenotype. When INI-4001 is used in combination with Al (OH)₃ and SARS-CoV-2 RBD antigen, it efficiently adsorbs to Al (OH)₃, promotes Th1 immunity and enhances SARS-CoV-2 neutralizing antibody responses. INI-4001 is applicable to research related to Powassan virus infection and COVID-19.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2549050-07-7
Formel: C₅₉H₁₀₉N₆O₁₃P
Molecular Weight:1141.50

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

INI-4001 Chemical Structure

CAS. Nr.: 2549050-07-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

TLR7

TLR8

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

In Vitro

INI-4001 (200 μg/mL; 1 h) adsorbs efficiently to mixed formulations of aluminum oxyhydroxide (AH) and aluminum phosphate (AP) in 2% glycerin, with no desorption observed in the presence of INI-2002 or SARS-CoV-2 RBD^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

INI-4001 (10 nmol; s.c.; prime-boost 2-4 weeks apart, single administration) adjuvant enhances the immunogenicity and protective efficacy of POW-VLP vaccines in mice, conferring 100% survival against lethal POWV-I and POWV-II challenge, reducing viral tissue burden, inducing durable antibody responses with 80% long-term survival 9 months post-boost, and mediating protection via humoral immunity independent of CD4⁺ or CD8⁺ T cells^[1].
INI-4001 (10 μg per mouse; i.m.; day 0, day 14, day 42) co-delivered with SARS-CoV-2 RBD and aluminum salt (Alhydrogel or Adju-phos) significantly enhances RBD-specific IgG and Th1-skewed IgG2c antibody titers, induces robust antigen-specific Th1 (IFNγ-producing) T cell responses, and improves surrogate viral neutralization activity in C57BL/6 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, 7 weeks old at vaccination)^[1]
Dosage:

10 nmol (prime-boost vaccination); 10 nmol (single vaccination)
Administration:

s.c.; prime-boost 2-4 weeks apart; single administration
Result:

Induced a mean log₁₀ IgG endpoint titer of 4.9, with 11/18 mice having measurable FRNT₅₀ neutralizing antibody titers.
Conferred 100% survival against lethal POWV-I challenge, compared to 50% survival with alum.
Reduced POWV-I viral RNA loads in the brain, liver, and spleen compared to mock-vaccinated mice post-challenge.
Enabled passive transfer of sera to protect 4/5 naïve mice from lethal POWV-I challenge.
Maintained 100% survival against lethal POWV-I challenge even after CD4⁺ or CD8⁺ T cell depletion.
Induced cross-reactive IgG antibodies to POWV-II and Langat virus, and conferred 100% survival against lethal POWV-II challenge, compared to 40% survival with alum; vaccinated mice had minimal weight loss (max ~3% initial weight) compared to alum-vaccinated survivors (10% weight loss).
Maintained significantly higher IgG and neutralizing antibody titers than alum-vaccinated mice for 36 weeks post-boost; enabled 80% survival against lethal POWV-I challenge 36 weeks post-boost.
Conferred 100% survival against lethal POWV-I challenge with single vaccination.

Chemical Information

CAS. Nr. 2549050-07-7
Molecular Weight 1141.50
Formel C₅₉H₁₀₉N₆O₁₃P
SMILES

OC1=NC2=C(N)N=C(O[C@@H](C)CCC)N=C2N1CC3CCN(CCOP(OCCOCCOCCOC[C@H](OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)(O)=O)CC3
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Crawford M W, et al. The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine[J]. npj Vaccines, 2025, 10(1): 156.

[2]. Siram K, et al. Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD. Vaccines (Basel). 2023;12(1):21. Published 2023 Dec 23. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

INI-4001

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

INI-4001 Related Classifications

HY-164485 Related Classifications